Johnson & Johnson (NYSE:JNJ) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.62. The company issued revenue guidance of $80.8-81.6 billion, compared to the consensus revenue estimate of $81.27 billion.Johnson & Johnson also updated its FY 2019 guidance to $8.53-8.63 EPS.
Several research analysts recently issued reports on the stock. Goldman Sachs Group set a $27.00 price target on shares of Melco Resorts & Entertainment and gave the stock a buy rating in a research report on Tuesday, May 28th. Zacks Investment Research downgraded shares of Hallmark Financial Services from a buy rating to a hold rating in a research report on Thursday. Credit Suisse Group restated a buy rating and set a $90.00 target price on shares of Bayerische Motoren Werke in a research report on Thursday. Barclays upped their target price on shares of from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the company an equal weight rating in a research report on Friday, June 21st. Finally, Raymond James restated a reduce rating and set a $48.00 target price (up from $45.00) on shares of Hancock Whitney in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $148.56.
Shares of JNJ opened at $132.07 on Friday. The company has a market cap of $350.10 billion, a PE ratio of 16.15, a P/E/G ratio of 2.28 and a beta of 0.70. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The business’s 50 day simple moving average is $138.36. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.57%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the business earned $2.10 EPS. Equities research analysts forecast that Johnson & Johnson will post 8.59 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.88%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s payout ratio is presently 46.45%.
In related news, Director Marillyn A. Hewson acquired 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.23% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Cost of Debt
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.